Provided by Tiger Trade Technology Pte. Ltd.

Rezolute, Inc.

5.09
+0.43009.23%
Post-market: 5.160.0699+1.37%19:57 EDT
Volume:6.50M
Turnover:33.28M
Market Cap:490.13M
PE:-6.33
High:5.64
Open:4.68
Low:4.65
Close:4.66
52wk High:11.46
52wk Low:1.07
Shares:96.29M
Float Shares:72.51M
Volume Ratio:7.56
T/O Rate:8.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8039
EPS(LYR):-0.9791
ROE:-81.73%
ROA:-48.74%
PB:4.20
PE(LYR):-5.20

Loading ...

BUZZ-Rezolute climbs after positive trial results for low blood sugar treatment

Reuters
·
Jun 02

Rezolute says 6 of 8 patients meet primary endpoint in Phase 3 upLIFT trial of ersodetug for tumor hyperinsulinism

Reuters
·
Jun 02

Rezolute - Topline Results for Uplift Study Expected in Second Half of 2026

THOMSON REUTERS
·
Jun 02

Rezolute - All 6 Responders Achieve Complete Discontinuation of Intravenous Glucose Requirements

THOMSON REUTERS
·
Jun 02

Rezolute - 6 of 8 Participants Meet Primary Endpoint Responder Criterion in Uplift Study

THOMSON REUTERS
·
Jun 02

Rezolute Announces Positive Interim Data for Its Phase 3 Uplift Study of Ersodetug in Tumor Hyperinsulinism

THOMSON REUTERS
·
Jun 02

Rezolute Is Maintained at Buy by Maxim Group

Dow Jones
·
May 15

Rezolute price target raised to $10 from $4 at Maxim

TIPRANKS
·
May 14

Maxim Group Keeps Their Buy Rating on Rezolute (RZLT)

TIPRANKS
·
May 14

High Growth Tech Stocks in US for May 2026

Simply Wall St.
·
May 14

Rezolute Q3 EPS $(0.16), Inline

Benzinga Earnings
·
May 13

Rezolute Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Rezolute Q3 net loss narrows as R&D expenses fall

Reuters
·
May 13

Rezolute Q3 FY26 net loss narrows to $16.2 million

Reuters
·
May 13

BRIEF-Rezolute Q3 EPS USD -0.16

Reuters
·
May 13

Press Release: Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Dow Jones
·
May 13

Rezolute management attends H.C. Wainwright BioConnect investor conference

Reuters
·
May 11

Rezolute Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
May 09

Rezolute publishes corporate presentation on ersodetug treatment for hyperinsulinism hypoglycemia

Reuters
·
May 02

Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026

TIPRANKS
·
May 02